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doi:10.1016/j.jtcvs.2003.11.023The report by Meyers and colleagues1 in this edition of the Journalregarding lung volume reduction surgery (LVRS) in high-risk pa-tients raises some interesting methodologic and ethical questions.The article was designed to assess the validity of patient selectioncriteria outlined in the first clinical publication of the NationalEmphysema Treatment Trial (NETT).2 In that article, NETT inves-
tigators identified a high-risk patient subset characterized by the combination of a
forced expiratory volume in 1 second (FEV1) less than or equal to 20% of predicted
and either a homogeneous pattern of disease or a diffusing lung capacity for carbon
monoxide (DLCO) less than or equal to 20% of predicted. This subgroup experi-
enced a high mortality and morbidity that outweighed the clinical benefit from the
procedure. The report herein disputes this conclusion by demonstrating that patients
with an FEV1 less than or equal to 20% and a DLCO less than or equal to 20% but
who have a heterogeneous pattern of disease can benefit from LVRS. The argument
goes that such patients should not be prevented from undergoing LVRS, as has been
specified in the recent Medicare coverage decision, which used the NETT results as
a guideline for reimbursement.
Therefore, the NETT suggests that a specific subset of patients constitute a
high-risk group that should not undergo LVRS, whereas Meyers and colleagues
believe that further subselection in this high-risk group can cull a subgroup with an
acceptable risk-benefit ratio. Who’s right?
Some readers will take this article at face value and agree with the conclusion of
Meyers and colleagues on the basis of reputation alone. The investigators at
Washington University have one of the largest and certainly the longest experiences
with LVRS and are acknowledged leaders in the field. However, there could be
unintended consequences if their criteria were universally followed. Their report
documents that this patient subset, although deriving significant benefit, is certainly
at high risk, with an increased chance of prolonged air leak and gastrointestinal
morbidity and an incidence of reoperation 3 times as great as that quoted in their
recent report of long-term results. Although it is true that their 5% mortality is
laudable, it is important to ask whether similar results can be achieved at other
institutions with less experience and expertise in LVRS. The Centers for Medicare
and Medicaid Services (CMS) has agreed to reimburse for LVRS at the 17
participating NETT centers and 31 non-NETT Medicare-approved lung transplant
centers around the country. Whereas the NETT institutions have documented their
expertise in LVRS, fewer than half of the non-NETT CMS-approved lung transplant
centers have a published experience with LVRS, and many have no ongoing
programs. Is it really ethical to suggest that these high-risk patients undergo LVRS
at institutions with little or no experience?
Other readers will agree with the NETT perspective, believing that a prospective
randomized controlled trial involving more than 1200 patients provides what are
arguably the best and most definitive data available on LVRS. The trial was
designed specifically to address the shortcomings, both theoretical and practical, of
the early LVRS reports; these included selection bias, survivorship bias, aggregate
data reporting, incomplete follow-up, and lack of medical controls. The recently
published report represents the best clinical and academic efforts of 18 centers (17
clinical centers and 1 coordinating center) recognized for their expertise in the arena





Lof LVR.3 Is it really reasonable to second-guess such a trial
and change selection criteria on the basis of a single report?
The simplest solution would seem to be to ask the NETT
investigators to review their data and sift out those 24 LVRS
patients whose parameters are identical to those cited in the
current report (FEV1 20% of predicted, DLCO 20% of
predicted, and heterogeneous disease). Analysis of this sub-
set might provide corroborative data that reinforce the ar-
gument for reimbursement in this patient subset. However,
there are significant methodologic shortcomings to this ap-
proach. The definitions for homogeneous/heterogeneous
disease are not necessarily consistent between the Washing-
ton University group and the NETT. Certainly, the deter-
mination was made by different investigators with no com-
mon base of experience. There is also no standardization of
methods to ensure similarity of patient selection or opera-
tive or perioperative management. Is a comparison of the
results of these 2 groups really valid?
In addition, there are the statistical problems of a post
hoc analysis in a retrospectively selected patient subset even
if the data are prospectively collected. The original NETT
data analysis was undertaken in a genuinely prospective
fashion, with hypotheses and potential predictors identified
before the institution of the trial. Repeated retrospective or
post hoc analyses can be interpreted as data mining, a
practice that is known to sometimes yield false but “statis-
tically significant” conclusions regarding clinical outcome
or patient predictors. When is such a post hoc analysis
legitimate, and should it be used to change selection crite-
ria?
This clinical dilemma is not new. Time and again over
the last few decades, we have seen “definitive” results from
prospective randomized trials being challenged subse-
quently by new and contradictory studies. This is the way
the science of surgery has evolved for decades. What is new
here is the active involvement by CMS in the selection of
patients. Their tailoring of the reimbursement policy to
coincide with the results of a single specific trial is a
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to the exclusion of patients who might be good candidates
for LVRS but whose specific clinical profiles were not
prospectively assessed in a randomized trial. Unfortunately,
this ethical dilemma is not limited to the specific high-risk
subset reported by Meyers and associates. What about 1
antitrypsin patients with lower lobe–predominant heteroge-
neous disease? Some investigators have reported good clin-
ical results in such patients. How about unilateral LVRS?
Many reports have outlined good success after unilateral
LVRS in patients with primarily unilateral disease or in
those with a contraindication to operation on a single side
(ie, prior thoracotomy or prior empyema). Unfortunately,
published CMS guidelines prohibit reimbursement for ei-
ther type of patient, and it is thus unlikely that we will be
able to determine the real value of LVRS in such patients
anytime soon.
The answers to all the questions cited will be neither
easily obtained nor quickly forthcoming now that reim-
bursement is strictly constrained. It is unlikely that the CMS
reimbursement guidelines will change in the near future.
Unfortunately, the difficult situation we find ourselves in is
likely to be repeated many times if CMS demands a “de-
finitive” trial to prove the efficacy for each new technology
and then tailors a reimbursement policy contingent on the
results of that single trial. It seems probable that there will
continue to be more questions than answers regarding re-
imbursement for new surgical technologies.
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